During the past decade, Imed19-privat conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Imed19-privat" are "Atrial Fibrillation" (1 trials), "Chronic Heart Failure" (1 trials), "Heart Failure" (1 trials) and "Prevention of Stroke or Systemic Embolism" (1 trials). Many other conditions were trialed in "Imed19-privat" in a lesser frequency.

Most popular intervention types in "Imed19-privat" are "Drug" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Apixaban" (1 trials), "Apixaban matching placebo" (1 trials), "Asundexian (BAY2433334)" (1 trials), "Asundexian matching placebo" (1 trials) and "BAY2413555 Dose 1" (1 trials). Other intervention names were less common.

The vast majority of trials in "Imed19-privat" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Imed19-privat". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Imed19-privat, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Imed19-privat, 1 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".